Leptin-driven microglial activation in FM — new immuno-metabolic chain candidate

One-paragraph summary

Review proposing leptin as the immuno-metabolic interface between peripheral metabolism and central microglial activation in FM. Clinical evidence cited: leptin levels correlate with FM pain severity and symptom burden, independent of BMI. Pathway claim: leptin → leptin receptor (LepR) → JAK2/STAT3, MAPK/ERK, PI3K/Akt → reactive microglial states + disrupted synaptic plasticity + sustained central sensitization. Selective leptin resistance is proposed as the mechanistic framework that explains preserved pronociceptive/inflammatory signaling despite impaired metabolic regulation. This is a new candidate chain — the immuno-metabolic chain — distinct from H1 (autoimmune), H2 (mast cell), H3 (predictive coding), and the HERV-mtDNA-mitochondrial loop. It connects FM to metabolic-syndrome literature and supplies a candidate mechanism for the FM-obesity / FM-insulin-resistance comorbidity patterns that the project has only partially addressed via Krupa 2024 (insulin resistance × depression).

Claims as triples

• leptin — elevated_in → fm_subset [evidence: review consolidation of clinical studies; confidence: emerging]
• leptin — correlates_with → fm_pain_severity_bmi_independent [evidence: review; confidence: emerging — clinical studies aggregated]
• leptin_receptor — activates → JAK2_STAT3 [evidence: established receptor pharmacology; confidence: established]
• leptin_receptor — activates → MAPK_ERK [evidence: established receptor pharmacology; confidence: established]
• leptin_receptor — activates → PI3K_Akt [evidence: established receptor pharmacology; confidence: established]
• leptin_receptor_signaling — promotes → reactive_microglial_state [evidence: review; confidence: emerging — preclinical primary work]
• selective_leptin_resistance — explains → preserved_pronociceptive_signaling_despite_metabolic_impairment [evidence: review's framework integration; confidence: inferred — mechanism proposal]
• immunometabolic_chain — operates_in → fm_subset [evidence: review's novel framing; confidence: emerging]

Methods note

Narrative review. Synthesizes clinical literature on leptin levels in FM, preclinical leptin-receptor pharmacology on microglia, and the broader immuno-metabolic interaction literature. The clinical claim (leptin correlates with FM pain severity, BMI-independent) is from cited primary studies; the mechanism claim is consolidation of receptor-pathway literature; the FM-specific selective-leptin-resistance interpretation is the review's own framing.

Limitations

• Narrative review with selection bias
• Clinical studies cited are heterogeneous (different leptin measurement methods, different FM cohorts)
• "BMI-independent" claim depends on adequate BMI adjustment; could be confounded by other metabolic factors (adipose distribution, visceral fat)
• Selective leptin resistance is a recognized concept (in obesity) but its FM-specific operationalization is novel and untested
• Doesn't address FM autoimmune-subtype vs metabolic-subtype stratification
• Doesn't reconcile with the existing H1/H2/H3 chains — leaves the integration question open

Open questions raised

• Q-IM-1 (new): Is FM-leptin elevation a primary causal driver of FM-microglial activation, or is it a downstream marker of a broader metabolic-dysregulation process? Genetic studies (LepR variants, leptin-pathway polymorphisms) in FM cohorts would test the causal direction.
• Q-IM-2 (new): Are there FM patients whose phenotype is dominantly immuno-metabolic (high leptin, insulin resistance, adipose-tissue inflammation) vs dominantly autoimmune (anti-SGC IgG+, anti-GFAP IgG+)? Subtype-mapping question.
• Q-IM-3 (new): Do leptin-pathway interventions (currently scarce in FM literature — leptin antagonists are in development for obesity/cancer cachexia) have therapeutic potential in immuno-metabolic-subtype FM? Repurposing question.
• Q-IM-4 (new): How does the immuno-metabolic chain interact with the H2 (MC) chain? Mast cells respond to leptin and adipose tissue is a major MC reservoir; the Amato 2026 lipedema-gfWAT framework already implicates adipose MC as FM-relevant. Leptin → adipose MC degranulation → systemic MC mediator release → microglial activation could be a unified immuno-metabolic-H2 pathway.

Triangulation notes

• Connects to Krupa 2024 insulin-resistance-depression bridge (already in ontology as insulin_resistance bridges fm_central_only): the immuno-metabolic chain extends Krupa's metabolic-MDD subtype framing to a full FM metabolic-subtype framework. Both papers support a metabolic-axis stratification of FM.
• Connects to Amato 2026 lipedema-gfWAT-MC framework (already in project): Amato establishes gluteofemoral adipose MCs as MC-estrogen-receptor-driven FM-comorbidity tissue. This paper extends the adipose-FM connection from MC to leptin-microglial axis. Joint framing: adipose tissue is the FM-comorbidity tissue producing both MC mediators AND leptin signals; both reach the CNS via different routes.
• Distinct from H1/H2/H3 chains: doesn't fit cleanly into autoimmune, mast cell, or predictive coding. Needs its own chain designation — proposing H4: immuno-metabolic chain.
• Compatible with subtype mapping: FM cohorts have known metabolic-syndrome subset; this chain offers the mechanism for why that subset has FM symptoms beyond chance comorbidity.

Bridges

• B-IM-1 (NEW candidate): Adipose tissue ↔ FM CNS via dual MC-mediator + leptin-signaling pathways. Bridging tier — predicted mechanism, partially supported by Amato 2026 (adipose MC) and this paper (leptin).
• Connection to existing insulin_resistance bridge: this paper supplies mechanism layer for the previously-noted insulin_resistance × fm_central_only bridge.

Cure-path-arm implications

• Leptin pathway interventions (leptin antagonists, leptin-receptor antagonists, JAK2 inhibitors) — currently scarce in FM literature. Should be added at "watchlist" tier for the immuno-metabolic-subtype FM cohort.
• Metformin + pioglitazone (already in cure-path-arms): the immuno-metabolic chain framing supplies mechanism justification for these metabolic-targeting interventions in FM.
• GLP-1 receptor agonists (semaglutide, etc.) — anti-inflammatory + leptin-modulating effects; not currently in cure-path-arms but worth evaluating for immuno-metabolic-subtype FM.

Confidence-tier framing

• Leptin elevation in FM subset: emerging (clinical studies aggregated)
• Leptin → microglial activation mechanism: emerging (preclinical anchored)
• Immuno-metabolic chain as distinct FM chain: inferred (novel framing, awaits subtype-stratified mechanism confirmation)
• Selective leptin resistance FM operationalization: inferred (extrapolation from obesity literature)

Chain-map update

• Propose adding H4: immuno-metabolic chain to the project's chain framework. Structure: adipose tissue → leptin + MC mediators → systemic signaling → microglial activation → central sensitization. Operates in FM subset characterized by metabolic-syndrome features. Distinct from but parallel to H1, H2, H3.